Biogen Total Current Liabilities from 2010 to 2024
| BIIB Stock | USD 157.90 0.11 0.07% |
Total Current Liabilities | First Reported 1985-12-31 | Previous Quarter 3.1 B | Current Value 5.4 B | Quarterly Volatility 1.5 B |
Check Biogen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biogen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 257.5 M, Interest Expense of 259.2 M or Selling General Administrative of 2.6 B, as well as many indicators such as Price To Sales Ratio of 3.62, Dividend Yield of 0.0022 or PTB Ratio of 2.4. Biogen financial statements analysis is a perfect complement when working with Biogen Valuation or Volatility modules.
Biogen | Total Current Liabilities |
Latest Biogen's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Biogen Inc over the last few years. Total Current Liabilities is an item on Biogen balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Biogen Inc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Biogen's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biogen's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Biogen Total Current Liabilities Regression Statistics
| Arithmetic Mean | 2,823,398,533 | |
| Geometric Mean | 1,882,633,621 | |
| Coefficient Of Variation | 46.04 | |
| Mean Deviation | 1,040,937,093 | |
| Median | 3,295,200,000 | |
| Standard Deviation | 1,299,779,602 | |
| Sample Variance | 1689427T | |
| Range | 4.9B | |
| R-Value | 0.83 | |
| Mean Square Error | 561966.7T | |
| R-Squared | 0.69 | |
| Significance | 0.0001 | |
| Slope | 241,619,614 | |
| Total Sum of Squares | 23651978.2T |
Biogen Total Current Liabilities History
About Biogen Financial Statements
Biogen stakeholders use historical fundamental indicators, such as Biogen's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Biogen investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biogen's assets and liabilities are reflected in the revenues and expenses on Biogen's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biogen Inc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 3.4 B | 3.6 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:Check out the analysis of Biogen Correlation against competitors. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.02) | Earnings Share 11.05 | Revenue Per Share 66.122 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0499 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.